Abstract
BackgroundPARP inhibition (PARPi) has demonstrated potent therapeutic efficacy in patients with BRCA-mutant ovarian cancer.1 However, acquired resistance to PARPi remains a major challenge in the clinic.2,3MethodsPARPi-resistant ovarian cancer mouse models...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have